Aveanna Healthcare Holdings Inc (AVAH) Stock Price & How to Invest

Aveanna Healthcare Holdings runs home and community care across 39 states, with concentrations in Texas, Pennsylvania and California. The largest business by far is Private Duty Services, which supplies skilled private duty nursing, therapy, school nursing and personal care to medically complex and chronically ill children, and which produced ~$536 million of the ~$648 million of first-quarter 2026 revenue. A smaller Home Health and Hospice segment (~$67 million in the quarter) serves mostly elderly patients and is paid by Medicare, and a Medical Solutions segment (~$46 million) delivers enteral nutrition and related products. Gross margins differ sharply by segment: ~27.9% in private duty nursing, ~53.7% in home health and hospice, ~44.7% in medical solutions, so mix shifts move the consolidated number.

The investment picture is a spread business financed with leverage. Aveanna buys nursing hours at a wage rate and bills them to Medicaid at a reimbursement rate, and the gap between those two, which management calls the spread rate, is the entire profit engine. That spread has been widening at the company level: first-quarter 2026 revenue rose ~15.9% and adjusted EBITDA rose ~25.2% to ~$84.4 million, and management raised full-year 2026 guidance twice, to ~$2.63 billion to ~$2.65 billion of revenue and ~$338 million to ~$342 million of adjusted EBITDA after closing the Family First Homecare acquisition on June 1, 2026. Against that, total indebtedness was ~$1.48 billion at April 4, 2026 on ~$240 million of book equity and ~$1.12 billion of goodwill, so the equity is a residual claim on a heavily financed cash flow stream, and the shares have already re-rated hard, up roughly 160% over the past year.

Payer concentration is the dominant risk: with ~81% of revenue tied to Medicaid and Medicaid managed care, a single adverse state budget or rate freeze reaches the income statement directly, and the Medicaid funding changes in the 2025 federal tax law leave states with less room to be generous. Leverage magnifies that, since net debt near ~$1.3 billion at the end of the first quarter (before the cash-funded Family First purchase) sits at roughly four times guided adjusted EBITDA against only ~$240 million of book equity. Caregiver supply is the operating constraint, and wage inflation running ahead of rate increases compresses the spread quickly, as the ~8.1% private duty cost rate increase in the first quarter showed. Aveanna has been responding to Department of Justice matters since October 2019, including antitrust grand jury subpoenas covering nurse wages, reimbursement rates and hiring in certain markets, and a 2023 civil investigative demand regarding its Comfort Care Hospice subsidiary, both of which the company says it cannot predict the outcome of. Finally, ~$1.12 billion of goodwill on ~$2.02 billion of assets means an impairment cycle would take book equity negative again, as it was as recently as 2024.

10 analysts publish price targets on AVAH, averaging $10.45 against a $9.49 price as of August 2026, or +10.1%. The published targets run from $8.00 to $13.00, a moderate spread, and the ratings split 8 buy, 3 hold, 0 sell. Over the last six months there have been 5 raises and 6 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full AVAH forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Aveanna Healthcare Holdings Inc. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. State Medicaid rate increases versus caregiver wages. Private duty revenue rate rose ~5.7% year over year in the first quarter of 2026, driven by reimbursement increases from various state Medicaid programs and managed Medicaid payers. The most optimistic published target, $13.00, assumes this works close to its best case.

The case against. Payer concentration is the dominant risk: with ~81% of revenue tied to Medicaid and Medicaid managed care, a single adverse state budget or rate freeze reaches the income statement directly, and the Medicaid funding changes in the 2025 federal tax law leave states with less room to be generous. The most pessimistic target, $8.00, is roughly what AVAH is worth if this bites instead.

Read the full bull and bear case on AVAH, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Aveanna Healthcare Holdings Inc's investor relations page or your broker.

• Revenue (TTM): ~$2.52B through Q1 2026 (fiscal 2025 was ~$2.43B)
• Q1 2026 results: Revenue ~$647.9M (+15.9%), net income ~$41.7M (~$0.19 diluted), adjusted EBITDA ~$84.4M (+25.2%)
• FY2026 guidance: Revenue ~$2.63B to ~$2.65B, adjusted EBITDA ~$338M to ~$342M
• Debt and leverage: ~$1.48B total indebtedness and ~$189M cash at April 4, 2026 (~$1.29B net debt, near 4x guided adjusted EBITDA) before the ~$175.5M cash-funded acquisition
• Medicaid exposure: ~59.2% Medicaid MCO plus ~21.8% direct Medicaid, ~9.9% Medicare, ~8.9% commercial
• Market cap / EV: ~$2.0B market cap on ~218M shares, roughly ~$3.5B enterprise value, near 10x guided adjusted EBITDA

Fiscal 2025 GAAP net income of ~$225.0M is not a clean earnings number: pre-tax income was only ~$106.9M, and the difference came mostly from a non-cash tax benefit tied to releasing a deferred tax valuation allowance, which is why a trailing P/E on AVAH looks far cheaper than the business is. Enterprise value to adjusted EBITDA is the more comparable frame, and near 10x it prices Aveanna between slower Medicare home health peers and faster-growing home and community platforms. Second-quarter 2026 results are scheduled for August 13, 2026, and the figures above predate them.

Other names that sit close to AVAH: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get AVAH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so AVAH sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where AVAH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

AVAH is a leveraged operator of a growing, Medicaid-funded service, so the reimbursement-rate cycle and the debt schedule, not the demand story, set the range of outcomes.

Whether AVAH is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AVAH a buy or a sell?, and where the stock could go from here in the AVAH stock forecast.

For income investors, whether AVAH pays a dividend and how the payout looks is covered in does AVAH pay a dividend? And to weigh AVAH against a peer, read the full side-by-side comparisons: AVAH vs ADUS and AVAH vs CHE.